Research
Hormonal
Intrauterine growth restriction (IUGR) and subsequent 'catch-up' growth program the body for increased risk of metabolic syndrome, hypertension, and diabetes in adulthood.
For those with a history of low birth weight, early monitoring of metabolic health is crucial. Preventing excessive childhood weight gain can mitigate the programmed risk for adult metabolic syndrome and hypertension.
GoodSupportsHIGH confidence
Epidemiologic studies over the past 15 yr have uncovered a consistent relationship between low birth weight and increased risk for developing adult metabolic syndrome... rapid compensatory growth in childhood is a significant enhancer of adult cardiovascular disease risk in offspring with intrauterine growth restriction (IUGR)...
Why this rating
Based on epidemiological cohort studies and animal models.
Source
Obesity-Initiated Metabolic Syndrome and the Kidney
Susan P. Bagby · Journal of the American Society of Nephrology · 2004
DOI 10.1097/01.asn.0000141965.28037.ee
narrative_reviewCited 258×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Abdominal (visceral) obesity is the primary initiator of metabolic syndrome, driving insulin resistance and multi-organ metabolic derangements through elevated free fatty acids, reduced adiponectin, and leptin resistance.Strong
- Insulin resistance is the essential common denominator of metabolic syndrome, driven by intracellular lipid accumulation (FFA, diacylglycerol) which interferes with insulin signaling pathways (IRS-1 phosphorylation).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →